京都医療センター

臨床研究センター

内分泌代謝高血圧研究部

発表論文

2020年

  • Miyazaki Y, Katanasaka Y, Tsutsui Y, Sunagawa Y, Funamoto M, Shimizu K, Shimizu S, Sari N, Yamakage H, Satoh-Asahara N, Toyama K, Suzuki M, Shimizu A, Wada H, Hasegawa K, Morimoto T. A randomized placebo-controlled, double-blind study of kosen-cha, a polymerized catechin-rich green tea, for obesity in pre-obese Japanese subjects. BPB Reports. 3: 202-207, 2020 (IF: 未掲載, CI: 未掲載) 査読付
  • Fujita K, Kada S, Kanai O, Hata H, Odagaki T, Satoh-Asahara N, Tagami T, Yasoda T. Quantitative SARS-CoV-2 antibody screening of healthcare workers in the southern part of kyoto city during the COVID-19 pre-pandemic period. Front Public Health. 8: 595348, eCollection, 2020. (IF: 3.709, CI: 8) 査読付
  • Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K, Shimizu M, Funada J, Takenaka T, Morita Y, Nakamura T, Fujimoto K, Matsubara H, Kato T, Unoki T, Takagi D, Wada K, Wada M, Iguchi M, Masunaga N, Ishii M, Yamakage H, Kusakabe T, Yasoda A, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M, Akao M, Hasegawa K, for the ANOX Study Investigators. Impact of smoking status on growth differentiation factor 15 and mortality in patients with suspected or known coronary artery disease: the ANOX study. J Am Heart Assoc. 9: e018217, 2020 (IF: 5.501, CI: 1) 査読付
  • Ikeda A, Yamaguchi K, Yamakage H, Abiko K, Satoh-Asahara N, Takakura K, Konishi I. Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer short title: prognostic value of serum LDH in ovarian cancer. Obstet Gynecol Sci. 63: 709-718, 2020 (IF: 未掲載, CI: 未掲載) 査読付
  • Kusakabe T, Yokota S, Shimizu M, Inoue T, Tanaka M, Ohue-Kitano R, Muranaka K, Yamakage H, Wada H, Hasegawa K, Satoh-Asahara N. Differential effects of sodium–glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db/db mice. BMJ Open Diabetes Res Care. 8: e001303, 2020 (IF: 3.388, CI: 3) 査読付
  • Kaneko H, Umakoshi H, Ishihara Y, Nanba K, Tsuiki M, Kusakabe T, Satoh-Asahara N, Yasoda A, Tagami T. Reassessment of urinary aldosterone measurement after saline infusion to predict subtype of primary aldosteronism. J Endocr Soc. 4: bvaa100, eCollection, 2020 (IF: none, CI: 1) 査読付
  • Isshiki M, Sakuma I, Hayashino Y, Sumita T, Hara K, Takahashi K, Shiojima I, Satoh-Asahara N, Kitazato H, Ito D, Saito D, Hatano M, Ikegami Y, Iida S, Shimada A, Noda M. Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration. Endocr J. 67: 1127-1138, 2020 (IF: 2.349, CI: 2) 査読付
  • Ono K, Wada H, Satoh-Asahara N, Inoue H, Uehara K, Funada J, Ogo A, Takahiro H, Fujita M, Shimatsu A, Hasegawa K. Effects of metformin on left ventricular size and function in hypertensive patients with type 2 diabetes mellitus: results of a randomized, controlled, multicenter, phase IV trial. Am J Cardiovasc Drugs. 20: 283-293, 2020 (IF: 3.571, CI: 1) 査読付
  • Kasahara M, Kuwabara Y, Moriyama T, Tanabe K, Satoh-Asahara N, Katsuya T, Hiramitsu S, Shimada H, Sato T, Saito Y, Nakagawa T. Intensive uric acid-lowering therapy in CKD patients: the protocol for a randomized controlled trial. Clin Exp Nephrol. 24: 235-241, 2020 (IF: 2.801, CI: 0) 査読付
  • Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K, Shimizu M, Funada J, Takenaka T, Morita11 Y, Nakamura T, Fujimoto K, Matsubara H, Kato T, Unoki T, Takagi D, Wada K, Wada M, Iguchi1 M, Masunaga N, Ishii M, Yamakage H, Kusakabe T, Yasoda A, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M, Akao M, Hasegawa K, for the ANOX study investigators. Distinct characteristics of VEGF-D and VEGF-C to predict mortality in patients with suspected or known coronary artery disease. J Am Heart Assoc. 9: e015761, 2020 (IF: 5.501, CI: 8) 査読付
  • Tanaka M, Yamakage H, Inoue T, Odori S, Kusakabe T, Shimatsu A, Satoh-Asahara N (corresponding). Beneficial effects of ipragliflozin on the renal function and serum uric acid levels in Japanese patients with type 2 diabetes: a randomized, 12-week, open-label, active-controlled trial. Intern Med. 59: 601-609, 2020 (IF: 1.271, CI: 6) 査読付
  • Yamakage H, Tanaka M, Inoue T, Odori S, Kusakabe T, Satoh-Asahara N (corresponding). Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: a randomized, controlled trial. J Diabetes Investig. 11: 653-661, 2020 (IF: 4.232, CI: 8) 査読付
  • Son C, Kasahara M, Tanaka T, Satoh-Asahara N, Kusakabe T, Nishimura K, Miyamoto Y, Kasama S, Hosoda K. Rationale, design, and methods of the study of comparison of canagliflozin vs. teneligliptin against basic mtabolic risks in patients with type 2 diabetes mellitus (CANTABILE study): protocol for a randomized, parallel-group comparison trial. Diabetes Ther. 11:347-358, 2020 (IF: 2.945, CI: 1) 査読付